Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 3Phase 4 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Urinary Bladder Neoplasms 7Non-Muscle Invasive Bladder Neoplasms 3Prostatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Carcinoma, Ovarian Epithelial 1Carcinoma in Situ 1

Interventions

Gemcitabine 12Mitomycin 6Docetaxel 4Radiotherapy 3BCG Vaccine 3tislelizumab 2erdafitinib 2dodecyl maltoside 2disitamab vedotin 2toripalimab 1pemigatinib 1pembrolizumab 1monalizumab 1linrodostat 1enzalutamide 1durvalumab 1bicalutamide 1avelumab 1Watchful Waiting 1Sugars 1Postoperative Period 1Pentosan Sulfuric Polyester 1Nonsteroidal Anti-Androgens 1Nivolumab 1Metformin 1Imiquimod 1Hyaluronic Acid 1High-Intensity Interval Training 1Gels 1Epirubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Non-Muscle Invasive Bladder Neoplasms × BCG Vaccine × Clear all
NCT06833073 2026-05-28

INTerpath-011

Merck Sharp & Dohme LLC

Phase 2 Recruiting
308 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT01697306 2025-01-30

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

A.O.U. Città della Salute e della Scienza

Phase 2 Completed
120 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06187506 2024-07-12

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Fudan University

Phase 2 Recruiting
20 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡